CA Patent

CA2760174A1 — Protein kinase inhibitors and uses thereof

Assigned to Pharmascience Inc · Expires 2013-06-01 · 13y expired

What this patent protects

The present invention relates to a new class of 5-aryl-5H-pyrrolo[3,2-d]pyrimidin-4-amines which contain 6,7-fused cycloalkyl and heterocycloalkyl ring systems. Compounds of this class have been found to be effective inhibitors of protein kinases: including members of the SRC an…

USPTO Abstract

The present invention relates to a new class of 5-aryl-5H-pyrrolo[3,2-d]pyrimidin-4-amines which contain 6,7-fused cycloalkyl and heterocycloalkyl ring systems. Compounds of this class have been found to be effective inhibitors of protein kinases: including members of the SRC and Tec kinase families. These compounds demonstrate the requisite physiochemical properties for use as pharmaceutical agents for the treatment of various proliferative, inflammatory and autoimmune diseases such as, but not limited to, cancer, arthritis, MS and the like.

Drugs covered by this patent

Patent Metadata

Patent number
CA2760174A1
Jurisdiction
CA
Classification
—
Expires
2013-06-01
Drug substance claim
No
Drug product claim
No
Assignee
Pharmascience Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.